Literature DB >> 18758897

Chronic myeloid leukemia in two patients with gastrointestinal stromal tumor.

Erina Sakamoto1, Tetsuji Sawada2, Harushi Osugi3, Hirohisa Nakamae1, Ki-Ryang Koh1, Takahisa Yamane1, Masahiko Ohsawa4, Kenichi Wakasa4, Masayuki Hino5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18758897     DOI： 10.1007/s12185-008-0151-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

Review 1.  Non-targeted and delayed effects of exposure to ionizing radiation: II. Radiation-induced genomic instability and bystander effects in vivo, clastogenic factors and transgenerational effects.

Authors:  William F Morgan
Journal:  Radiat Res       Date:  2003-05       Impact factor: 2.841

Review 2.  A mutator phenotype in cancer.

Authors:  L A Loeb
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

Review 3.  Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors:  M Miettinen; J Lasota
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

4.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

5.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

Authors:  A T van Oosterom; I Judson; J Verweij; S Stroobants; E Donato di Paola; S Dimitrijevic; M Martens; A Webb; R Sciot; M Van Glabbeke; S Silberman; O S Nielsen
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

6.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

7.  A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia.

Authors:  Markku Miettinen; Ewa Kraszewska; Leslie H Sobin; Jerzy Lasota
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

8.  Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

Authors:  J Verweij; A van Oosterom; J-Y Blay; I Judson; S Rodenhuis; W van der Graaf; J Radford; A Le Cesne; P C W Hogendoorn; E D di Paola; M Brown; O S Nielsen
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.